Attempt of Cancer Pain Control with the aid of Anti-TRPV Channel Antibody

借助抗TRPV通道抗体控制癌痛的尝试

基本信息

  • 批准号:
    18613001
  • 负责人:
  • 金额:
    $ 2.61万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

This project intends to produce a new therapeutic antibody that would ameliorate protracted cancer pain syndrome by utilizing a new finding that a cation channel called TRPV1 constitutes one of the final pathway of signaling pain sensation in neuronal cells. Although the polyclonal antibody raised against the bacterially produced TRPV1 E3 bop recognized the antigen protein with a high titer in Western blotting analysis, the antibody reacted only weakly with the full-length TRPV1 channel protein expressed in HEK293 cultured Dells. Therefore, in order to obtain a high titer antibody against the TRPV1 E3 lap, we have established several hybridoma clones that produce monoclonal antibodies interacting with a bacterially produced fission protein containing the TRPV1 E3 loop peptide. Screening of monoclonal antibodies that specifically recognize TRPV1 protein expressed in HEK293 cells yielded several hybridoma clones. Also, it is revealed that, as expected, most of the initially established hybridomas produce monoclonal antibodies that recognize only the bacterially expressed protein. Next, we searched for the antibodies that recognize TRPV1 channel protein expressed on cell surface in non denaturing condition by live-cell ELISA. We now continue single cell cloning of a couple of hybridomas that produce monoclonal antibodies recognizing TRPV1 protein expressed on live cell surface.
该项目旨在通过利用一项新发现,即称为TRPV 1的阳离子通道构成神经元细胞中传递疼痛感觉信号的最终途径之一,生产一种新的治疗性抗体,以改善持久性癌症疼痛综合征。尽管针对细菌产生的TRPV1 E3 bop产生的多克隆抗体在Western印迹分析中以高滴度识别抗原蛋白,但该抗体仅与HEK293培养的Dell中表达的全长TRPV1通道蛋白弱反应。因此,为了获得针对TRPV1 E3 lap的高滴度抗体,我们建立了几个杂交瘤克隆,其产生与细菌产生的含有TRPV1 E3环肽的分裂蛋白相互作用的单克隆抗体。筛选特异性识别HEK293细胞中表达的TRPV1蛋白的单克隆抗体产生了几个杂交瘤克隆。此外,正如预期的那样,揭示了大多数最初建立的杂交瘤产生仅识别细菌表达的蛋白质的单克隆抗体。接下来,我们通过活细胞ELISA寻找在非变性条件下识别在细胞表面表达的TRPV 1通道蛋白的抗体。我们现在继续单细胞克隆的一对夫妇的杂交瘤,产生单克隆抗体识别TRPV1蛋白表达在活细胞表面。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Functional analysis of an intracellular chloride channel protein that binds to histamine H3 receptor
与组胺 H3 受体结合的细胞内氯离子通道蛋白的功能分析
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Xu A-Jin;ed. al.;中川貴之;Sato T. ed. al.;Saito M. ed. al.;中川貴之;Maeda K. ed. al.
  • 通讯作者:
    Maeda K. ed. al.
ミトコンドリアの機能傷害により細胞死を誘導する新規自殺遺伝子治療法の評価
通过线粒体功能障碍诱导细胞死亡的新型自杀基因疗法的评估
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    中川貴之;大坪泰斗;八谷有美;金子周司;佐藤岳哉
  • 通讯作者:
    佐藤岳哉
イラスト薬理学
插图药理学
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    出山諭司;平田美紀枝;中川貴之;金子周司;南 雅文;Sato T. ed. al.;柳澤輝行(監訳)
  • 通讯作者:
    柳澤輝行(監訳)
Low expression of cell-surface thromboxane A2 receptor beta-isoform through the negative regulation of its membrane traffic by proteasomes
通过蛋白酶体对其膜运输的负调节,细胞表面血栓素 A2 受体 β-异构体的低表达
MDMA,5-MeO-DIPT,メタンフェタミンの慢性投与による逆耐形成と場所嗜好性
长期服用 MDMA、5-MeO-DIPT 和甲基苯丙胺导致的反向耐受性和位置偏好
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jin;D.;Liu;H.-X.;Hashii;M.;Yokovama;S.;Koizumi;K.;Lopatina;O.;Islam;S.;Md.;Higashida;H;瀧野奈緒子
  • 通讯作者:
    瀧野奈緒子
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YANAGISAWA Teruyuki其他文献

YANAGISAWA Teruyuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YANAGISAWA Teruyuki', 18)}}的其他基金

Molecular and Applied Pharmacology of Subunits of Ion Channels as Biosensors
作为生物传感器的离子通道亚基的分子和应用药理学
  • 批准号:
    10559002
  • 财政年份:
    1998
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
Molecular Pharmacology of Selective beta3-Adrenergic Receptors
选择性 β3-肾上腺素能受体的分子药理学
  • 批准号:
    07557327
  • 财政年份:
    1995
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Cellular Pharmacology of Hyperpolarization-Relaxation Coupling
超极化弛豫耦合的细胞药理学
  • 批准号:
    07457020
  • 财政年份:
    1995
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Studies of membrane-associated enzyme activities which are regulated by membrane potential
受膜电位调节的膜相关酶活性的研究
  • 批准号:
    05670082
  • 财政年份:
    1993
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Mechanisms of vasodilation by K^+ channel openers
K^通道开放剂的血管舒张机制
  • 批准号:
    02670076
  • 财政年份:
    1990
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Developing behavioural methods to assess pain in horses
开发评估马疼痛的行为方法
  • 批准号:
    2686844
  • 财政年份:
    2025
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Studentship
Identifying mechanisms and novel treatments of bone pain - closing the gap to the clinic. BonePainIII
确定骨痛的机制和新疗法——缩小与临床的差距。
  • 批准号:
    EP/Y036956/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Research Grant
An innovative biofeedback enhanced adaptive extended reality (XR) device to reduce perinatal pain and anxiety during and after childbirth
一种创新的生物反馈增强型自适应扩展现实 (XR) 设备,可减少分娩期间和分娩后的围产期疼痛和焦虑
  • 批准号:
    10097862
  • 财政年份:
    2024
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Collaborative R&D
Resilience Factors, Pain, and Physical Activity in Adolescent Chronic Musculoskeletal Pain
青少年慢性肌肉骨骼疼痛的弹性因素、疼痛和体力活动
  • 批准号:
    10984668
  • 财政年份:
    2024
  • 资助金额:
    $ 2.61万
  • 项目类别:
Optic: A solution to Events Related Terrorism and Event Security Pain Points
Optic:事件相关恐怖主义和事件安全痛点的解决方案
  • 批准号:
    10084791
  • 财政年份:
    2023
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Collaborative R&D
Partnering For Pain: Identifying and actioning the Top 10 priorities for pediatric chronic pain in Canada
携手应对疼痛:确定加拿大儿科慢性疼痛的十大优先事项并采取行动
  • 批准号:
    485086
  • 财政年份:
    2023
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Operating Grants
Human Pain Seminar Series Summit 2024-Advances in Pain Neuroimaging: harnessing individual differences to delineate mechanisms and biomarkers of disease
2024年人类疼痛研讨会系列峰会-疼痛神经影像学进展:利用个体差异来描述疾病的机制和生物标志物
  • 批准号:
    487851
  • 财政年份:
    2023
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Miscellaneous Programs
Empowering youth with sickle cell pain: National clinical implementation of an effective mHealth innovation
帮助患有镰状细胞性疼痛的年轻人:有效的移动医疗创新的国家临床实施
  • 批准号:
    498863
  • 财政年份:
    2023
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Operating Grants
Partnering For Pain: Identifying and actioning the Top 10 priorities for pediatric chronic pain in Canada
携手应对疼痛:确定加拿大儿科慢性疼痛的十大优先事项并采取行动
  • 批准号:
    485109
  • 财政年份:
    2023
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Operating Grants
Multimodal opioid-sparing postoperative pain protocol versus standard of care for patients undergoing knee and shoulder arthroscopy: a randomized controlled trial and knowledge translation strategy
多模式阿片类药物保留术后疼痛方案与接受膝关节和肩关节镜检查的患者的护理标准:随机对照试验和知识转化策略
  • 批准号:
    485091
  • 财政年份:
    2023
  • 资助金额:
    $ 2.61万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了